|Application ||WB, E|
|Other Accession||Q8BG30, NP_005654.3|
|Calculated MW||57277 Da|
|Antigen Region||251-279 aa|
|Other Names||Negative elongation factor A, NELF-A, Wolf-Hirschhorn syndrome candidate 2 protein, NELFA, WHSC2|
|Target/Specificity||This WHSC2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 251-279 amino acids from the Central region of human WHSC2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||WHSC2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Essential component of the NELF complex, a complex that negatively regulates the elongation of transcription by RNA polymerase II. The NELF complex, which acts via an association with the DSIF complex and causes transcriptional pausing, is counteracted by the P-TEFb kinase complex. Probably required to interact with the RNA polymerase II complex.|
|Tissue Location||Ubiquitous. Expressed in heart, brain, placenta, liver, skeletal muscle, kidney and pancreas. Expressed at lower level in adult lung. Expressed in fetal brain, lung, liver and kidney.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene is expressed ubiquitously with higher levels in fetal than in adult tissues. It encodes a protein sharing 93% sequence identity with the mouse protein. Wolf-Hirschhorn syndrome (WHS) is a malformation syndrome associated with a hemizygous deletion of the distal short arm of chromosome 4. This gene is mapped to the 165 kb WHS critical region, and may play a role in the phenotype of the WHS or Pitt-Rogers-Danks syndrome. The encoded protein is found to be capable of reacting with HLA-A2-restricted and tumor-specific cytotoxic T lymphocytes, suggesting a target for use in specific immunotherapy for a large number of cancer patients. This protein has also been shown to be a member of the NELF (negative elongation factor) protein complex that participates in the regulation of RNA polymerase II transcription elongation.
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :
Narita, T., et al. Mol. Cell 26(3):349-365(2007)
Olsen, J.V., et al. Cell 127(3):635-648(2006)
Beausoleil, S.A., et al. Nat. Biotechnol. 24(10):1285-1292(2006)
Ping, Y.H., et al. J. Biol. Chem. 276(16):12951-12958(2001)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.